Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Potassium-transporting ATPase

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1995

6

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Active duodenal ulcer

6

Erosive esophagitis

6

Gastric ulcer

6

Gastroesophageal reflux disease

6

Heartburn

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

6

Primary

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Takeda Chemical Industries

6

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

PUBCHEM

6

EPA CompTox

4

SMS_ID

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DRUGS FOR ACID RELATED DISORDERS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Proton pump inhibitors

2

Combinations for eradication of Helicobacter pylori

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LANSOPRAZOLE

0K5C5T2QPG

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1995

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Gastroesophageal reflux disease

Active duodenal ulcer

Erosive esophagitis

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain h...

ealing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

AG-2000 FREE BASE

7EMR32786O

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1995

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Gastroesophageal reflux disease

Active duodenal ulcer

Erosive esophagitis

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain h...

ealing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

LEVOLANSOPRAZOLE

FB55O16184

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Gastroesophageal reflux disease

Active duodenal ulcer

Erosive esophagitis

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain h...

ealing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

DEXLANSOPRAZOLE SESQUIHYDRATE

HS2S9VK3NH

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Gastroesophageal reflux disease

Active duodenal ulcer

Erosive esophagitis

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain h...

ealing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

LANSOPRAZOLE SODIUM

GV9NY1U369

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1995

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Gastroesophageal reflux disease

Active duodenal ulcer

Erosive esophagitis

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain h...

ealing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

DEXLANSOPRAZOLE

UYE4T5I70X

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Gastroesophageal reflux disease

Active duodenal ulcer

Erosive esophagitis

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain h...

ealing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1